SCHEMBL5577009

SCHEMBL5577009

Nc1ccccc1C(=O)c1c(N)cccc1[C]=O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.50
GAA P10253 1/20 0.50
HSD17B10 Q99714 7/20 0.41
TP53 P04637 1/20 0.41
ALOX15 P16050 1/20 0.41
ALDH1A1 P00352 5/20 0.41
CFTR P13569 1/20 0.41
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39
CA9 Q16790 1/20 0.39
MMP2 P08253 1/20 0.38
ESRRA P11474 3/20 0.37
HSP90AA1 P07900 1/20 0.37
NTSR1 P30989 1/20 0.37
NPC1 O15118 4/20 0.36
RAB9A P51151 4/20 0.36
KDM4E B2RXH2 3/20 0.36
RECQL P46063 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
TSHR P16473 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16099810 0.84 MAPT (0.52) MAPTGAAHSD17B10ALDH1A1CA1
SCHEMBL16099809 0.84 MAPT (0.55) MAPTGAAHSD17B10TP53ALOX15
SCHEMBL5575993 0.77 PBRM1 (0.54) MAPTGAAHSD17B10ALDH1A1CA1
SCHEMBL30790667 0.74 MAPT (0.74) MAPTGAAHSD17B10TP53ALOX15
SCHEMBL112507 0.74 MAPT (0.74) MAPTGAAHSD17B10TP53ALOX15
SCHEMBL23881551 0.73 MAPT (0.55) MAPTGAAHSD17B10TP53ALOX15
SCHEMBL30089335 0.73 MAPT (0.55) MAPTGAAHSD17B10TP53ALOX15
Hydrochloric Acid SCHEMBL11745887 0.72 MAPT (0.71) MAPTGAAHSD17B10TP53ALOX15
Ammonia Solution, Strong SCHEMBL10992665 0.72 MAPT (0.71) MAPTGAAHSD17B10TP53ALOX15
SCHEMBL8764887 0.72 MAPT (0.71) MAPTGAAHSD17B10TP53ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1634079-A1 SCREENING METHOD FOR SUBSTANCES BINDING TO MEROZOITE SURFACE PROTEIN-1/42 MEDICAL RESEARCH COUNCIL (GB) 2006-03-15 EP claimed
WO-2004113920-A1 SCREENING METHOD FOR SUBSTANCES BINDING TO MEROZOITE SURFACE PROTEIN-1/42 MEDICAL RESEARCH COUNCIL (GB) 2004-12-29 WO claimed
US-20070003987-A1 Screening method for substance binding to merozoite surface protein-1/42 MEDICAL RESEARCH COUNCIL (GB) 2007-01-04 US disclosed
WO-1994013277-A2 USE OF DINAPHTHALENES COMPOUNDS AS ANTIPROLIFERATIVE AGENTS IMPERIAL CANCER RESEARCH TECHNOLOGY LIMITED (GB) 1994-06-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070003987-A1 Screening method for substance binding to merozoite surface protein-1/42 CD2BP2, MASP2, CD14 MAPT 4427/4885GAA 3513/4885HSD17B10 4047/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.